Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade
- First Online:
There is no doubt that paediatric immunization prevents serious diseases, but the administration of these vaccines to healthy children also involves risks of adverse drug reactions (ADRs), some of which are potentially serious. The current body of evidence on ADRs from immunization therapy at the population level is partly contradictory across countries, time periods and childhood immunization programmes. The objective of our study was to characterize reported adverse events (AEFIs) following immunization in Danish children.
Adverse events (AEFIs) in 0- to 17-year-old children and adolescents reported to the Danish Medicines Agency (DKMA) between 1998 and 2007 were analysed. The unit of analysis was one AEFI. Data were categorized with respect to time, age, and gender of the children, suspected vaccines, category and seriousness of the AEFIs, and reporting rate.
During the study period, the DKMA received 1,365 reports covering 2,600 AEFIs, corresponding to 60% of all adverse events reported for children. One third of the AEFIs were classified as serious, and two deaths were reported. The annual number of serious AEFIs remained constant during the study period. Approximately 80% of AEFIs were reported in children aged 0–2 years. Of all reported AEs, 45% were in the category “general disorders and administration site conditions”, followed by the categories “skin and subcutaneous tissue disorders” (20% of total AEFIs) and “nervous system disorders” (16% of total AEFIs). The largest share of serious events was from the category “nervous system disorders” (33% of serious AEFIs). The most frequently reported serious AEs were febrile convulsions, pyrexia, and injection-site reactions.
In Denmark, a large number of AEFIs following paediatric immunization have been reported, but the majority of cases were non-serious.
KeywordsChildren Vaccines Pharmacoepidemiology Immunization Denmark
- 3.O’Brien KK (2009) Pharmacists’ role in preventing vaccine-preventable diseases. US Pharm 34:39–45Google Scholar
- 11.Mansoor O, Pillans PI (1997) Vaccine adverse events reported in New Zealand 1990–1995. NZ Med J 110:270–272Google Scholar
- 20.Aagaard L, Hansen EH (2010) Adverse drug reactions reported for systemic antibacterials in Danish children over a decade. Br J Clin Pharmacol 70:765–768Google Scholar
- 21.The Danish National Board of Health. The children’s vaccination schedule in Denmark, 2009. Available at: (http://www.sst.dk). Accessed 3 June 2010
- 22.Summary of product information. MFR vaccine. Available at: (http://www.smi.dk). Accessed 3 June 2010
- 23.Summary of product information. Ditekipol/Act-Hib vaccine. Available at: (http://www.smi.dk). Accessed 3 June 2010
- 25.Roden S, Gibbs T (2007) CIOMS Working Groups and their contribution to pharmacovigilance. In: Mann RD, Andrews EB (eds) Pharmacovigilance, 2nd edn, chapter 23. John Wiley & Sons, Chichester, pp 287–305Google Scholar
- 26.MedDRA. Available at: http://www.meddramsso.com (last accessed June 3 2010) [password required]
- 27.Pharmacovigilance: medicinal products for human use and veterinary products, vol. 9. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/homev9.htm. Accessed 3 April 2010
- 28.Infomedia. Available at: http://www.infomedia.dk. Accessed 20 November 2009
- 29.Glissman S (2005) Danish Supreme Court rules that child with autism developed in temporal relation with MMR vaccination is not entitled to compensation. Euro Surveill 10:E050428.3Google Scholar